Comment on: the tumour
Lixia Xu,Qingxia Yang,C. Tang,M. Kuang
2022-01-01
Abstract:HepatoBiliary Surg Nutr 2022;11(2):280-282 | https://dx.doi.org/10.21037/hbsn-21-519 Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide (1). Resident immune cell populations within the liver, which is considered the largest immune organ, increase the pathological complexity of HCC (2). Innate lymphoid cells (ILCs), recently identified leukocytes, are a family of innate immune cells with similar characters to T lymphocytes. ILCs largely exist in intestinal mucosal tissue and regulate intestinal inflammation, mucosal defense, and tissue repair in gut disease processes (3). Unlike T cells, ILCs lack antigenspecific receptors; therefore, they cannot directly mediate antigen-specific responses (4). However, they can be activated by cytokines and/or natural cytotoxic receptors (such as NKp44) (5). ILCs are a highly heterogeneous cell population with high plasticity. Based on the expression of transcription factors and the production of different cytokines, ILCs can be divided into ILC1, ILC2, and ILC3, which are counterparts of the three main helper T cell subsets (Th1, Th2, and Th17) (6). Although ILCs can be detected in various tumor types, their specific contribution to tumor immunity is yet to be thoroughly elucidated. In a recently published article in Gut, Heinrich et al. (7) d i scovered that ILC-control l ing cytokines were differentially expressed in non-tumor and tumor tissues of patients with HCC. Among the differentially expressed cytokine genes, 3 cytokines (IL-1β, IL-33, and TGF-β) were shown to affect the plasticity and function of ILCs. Specifically, it was shown that TGF-β can affect the plasticity from NK cells to ILC1s, that IL-33 triggers an ILC2 response, and that IL-1β participates in the plasticity of ILC3s to ILC1s. IL-33 was found to be significantly associated with better overall survival in an HCC cohort from The Cancer Genome Atlas (TCGA) database. On the other hand, one previous study showed that IL-1β and IL23 could promote the differentiation from ILC1s to ILC3s, while ILC3s could differentiate to ILC1s in the presence of IL-12 and IL-18 (8). These studies indicate that specific cytokines are crucial in regulating the plasticity and immune functions of ILCs. The distribution of ILC subsets is not balanced in human tissues, including tumors, and their frequencies can differ significantly among individuals. Heinrich et al. used the simultaneous measurement of protein and RNA expression at the single-cell level to accurately identify the precise signatures of ILC subpopulations (7). They revealed a significant increase in ILC2s from non-tumor to tumor tissues in most of the patients with HCC analyzed in their study, while ILC3 exhibited an opposite trend (7). Furthermore, the ratio of ILC2 to ILC1 increased from non-tumor to tumor tissues in most patients (7). ILC2 can participate in the antitumor immune response by producing IL-5 and IL-13 to recruit eosinophils to the tumor site and restrict tumor growth (9). However, ILC2s have also been reported as a tumor accomplice in a variety of tumor environments, including breast cancer, gastric cancer, and prostate cancer, with their tumor-promoting functions Editorial